Opus Genetics wins FDA approval for RYZUMVI in presbyopia
Opus Genetics has secured FDA approval of a supplemental New Drug Application for phentolamine ophthalmic solution 0.75% (RYZUMVI) in the treatment of presbyopia in adults, marking the company's second approved product in the United States. The decision, announced on 16 October 2026, broadens RYZUMVI's existing label, which already covers pharmacologically induced mydriasis.
The approval triggers a milestone payment to Opus Genetics under its global licensing agreement with Viatris, which holds exclusive US commercialisation rights. Financial terms of the milestone were not disclosed.
Trial evidence and mechanism
The supplemental approval rests on data from two pivotal Phase 3 studies, VEGA-2 and VEGA-3, both of which met their primary and all key secondary efficacy endpoints. No treatment-related serious adverse events were reported across either trial. The most common ocular adverse reaction in the presbyopia studies was conjunctival hyperemia, occurring in 21% of subjects, followed by instillation site irritation in 16%. The majority of adverse reactions were described as mild, transient and self-resolving.
RYZUMVI works through a sympatholytic mechanism, blocking alpha-1 adrenergic receptors on the iris dilator muscle to reduce pupil diameter. The formulation is preservative-free and is designed to improve near vision without engaging the ciliary muscle, a distinction the company argues avoids the accommodation-related side effects associated with earlier miotic approaches.
George Magrath, chief executive of Opus Genetics, said the approval "underscores our clinical and regulatory capabilities" and reflects the company's focus on unmet needs in ophthalmic care. He said the company looks forward to working with Viatris to bring the product to patients.
Market context and competitive landscape
Presbyopia affects an estimated 90% of US adults over the age of 45, making it one of the largest underserved ophthalmic indications by population size. Until recently, pharmacological options were limited, with the market dominated by corrective lenses and surgical approaches such as LASIK monovision and refractive lens exchange.
The presbyopia eye-drop category has attracted several entrants in recent years. Allergan's pilocarpine-based Vuity (pilocarpine HCl 1.25%) received FDA approval in 2021 and was the first prescription eye drop in the indication. RYZUMVI's alpha-adrenergic mechanism differentiates it from pilocarpine-based products, which act on the ciliary muscle directly and carry a higher incidence of headache and brow ache. Whether that mechanistic distinction translates into a durable prescribing preference will depend on real-world tolerability data and the commercial execution of Viatris, the company's larger partner.
For Opus Genetics itself, the commercial upside is indirect: milestone and royalty payments from Viatris rather than direct sales. The company's core pipeline centres on gene therapies for inherited retinal diseases, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with five additional AAV-based programmes in earlier development. Phentolamine is simultaneously being evaluated in the Phase 3 LYNX programme for dim-light vision disturbances after keratorefractive surgery, a potential further label extension that could deliver additional milestone payments if that readout is positive.
The approval is a near-term cash catalyst for a company whose principal pipeline remains in clinical development, and investors will weigh it accordingly against the longer timeframe and risk profile of its gene therapy assets.